News

In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.

Ruth Beadle, head, global supply chain, Sanofi, discusses how digital integration, advanced planning, and sustainability goals are transforming end-to-end supply chain operations to improve scale, speed, and environmental impact.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

An NEJM study explores how this loss—following Medicaid disenrollment—affects beneficiaries.

In the third part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, dives into the barriers limiting AI and automation’s widespread adoption in R&D.

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day delivery.

Ruth Beadle, head, global supply chain, Sanofi, discusses the company’s multi-year effort to build an AI-powered, end-to-end supply chain focused on improving service, resilience, and cost efficiency.

In an exclusive sit-down with Pharma Commerce, Anne Cassity, senior vice president of government affairs for the National Community Pharmacists Association (NCPA), discusses pending legislation that could affect the impact of PBM pricing.

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

Ruth Beadle, head, global supply chain, Sanofi, explains how the company balances daily operations with long-term transformation efforts to ensure timely delivery of critical medications to patients.

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

Trump anticipates that the executive order will help lower drug prices by 30% to 80%.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, discusses the obstacles in documenting and proving DSCSA compliance.

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

In the third part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, shares the challenges that stakeholders are encountering, along with a possible change to the national drug code that could be on the way.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

In the second part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, comments on stakeholders’ overall preparedness for complying with the latest enforcement deadlines.